Related Experiment Video

Updated: Jan 16, 2026

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Therapeutic

Servando Hernandez Vargas1, Solmaz Aghaamiri1, Jack T Adams1

  • 1The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Current Oncology (Toronto, Ont.)
|September 26, 2025
PubMed

Insights

Somatostatin receptor 2 (SSTR2) is overexpressed in hepatocellular carcinoma (HCC) and linked to poorer survival. High SSTR2 expression activates cancer pathways, suggesting it's a therapeutic target for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Somatostatin receptor 2 (SSTR2), a G protein-coupled receptor, is overexpressed in hepatocellular carcinoma (HCC).
  • Emerging evidence suggests SSTR2 has a complex role in cancer, but its function in HCC is poorly understood.
  • This study investigates the molecular landscape of SSTR2 in HCC and its therapeutic potential.

Purpose of the Study:

  • To systematically investigate the molecular landscape associated with SSTR2 expression in HCC.
  • To evaluate SSTR2 as a potential therapeutic target in HCC.

Main Methods:

  • Assessed SSTR2 expression across 22 tumor types using TNMplot and The Human Protein Atlas.
  • Performed integrative analysis of TCGA data (transcriptomics, proteomics, copy number alterations) to stratify HCC patients.
  • Utilized SRplot for Gene Ontology enrichment analysis and GEO datasets for Kaplan-Meier survival analysis.

Main Results:

  • SSTR2 is moderately expressed in most HCC tumors and elevated expression correlates with significantly poorer overall and disease-specific survival.
  • High SSTR2 levels are associated with activation of oncogenic signaling pathways, including cell proliferation, EMT, angiogenesis, and metastasis.
  • SSTR2 expression positively correlates with receptor tyrosine kinases and oncogenes involved in HCC progression.

Conclusions:

  • SSTR2 is not just a biomarker but may actively contribute to HCC pathogenesis by modulating oncogenic pathways.
  • These findings support the development of SSTR2-targeted therapies to inhibit tumor growth and invasion in HCC.
Keywords:
SSTR2hepatocellular carcinomaoverall survivaltumorigenesis

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K